Drug profile · INN
sasanlimab
ZUMRAD
sasanlimab (ZUMRAD) is a programmed cell death protein 1 antagonist.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01FF
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — sasanlimab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
sasanlimab (ZUMRAD) is a programmed cell death protein 1 antagonist.
Key facts
INN sasanlimab
Brand ZUMRAD
Mechanism Programmed cell death protein 1 antagonist
Target Programmed cell death protein 1
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FF
Mechanism of action
Programmed cell death protein 1 antagonist
Primary target: Programmed cell death protein 1
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sasanlimab?
sasanlimab (ZUMRAD) is a programmed cell death protein 1 antagonist.
What is the brand name for sasanlimab?
ZUMRAD is a marketed brand name for sasanlimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.